Matches in SemOpenAlex for { <https://semopenalex.org/work/W4247521257> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4247521257 endingPage "30" @default.
- W4247521257 startingPage "1" @default.
- W4247521257 abstract "Background Rapid Rituximab infusion has become increasingly popular globally. Although pharmaceutical manufacturers recommend second and subsequent infusions to run over 2-3 hours, many cancer centres have changed their clinical practice based on their own research and the results from other primary studies. Such research studies claim that it is safe to administer Rituximab rapidly among cancer patients especially in Non Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). In addition, the studies suggest that the rapid infusion of Rituximab also results in benefits of cost saving and better resource utilisation. However, these studies have not been critically appraised for their validity and application to the global population. No previous systematic reviews on this topic have been identified. Objective The objective of this review was to critically appraise, synthesise and present the best available evidence related to the safety of rapid Rituximab infusion among adult patients with NHL and CLL. Inclusion criteria Type of participants The participants of interest were adults aged 18 years old and above who had a diagnosis of NHL or CLL at any stage, have had prior exposure to Rituximab and received Rituximab with or without combination of any chemotherapy. Type of intervention The intervention of interest was rapid Rituximab infusion to be completed in 120 minutes or less. Type of studies The studies of interest were both experimental and non-experimental studies. Type of outcomes The primary outcomes of interest were the presence of acute adverse reactions and their severity. The secondary outcomes of interest were the management of the acute adverse reactions and patient mortality rate resulting from adverse reactions. Search strategy The search sought to identify published and unpublished studies from 1997 till 2010. A three-step search strategy was used for electronic databases, grey literature and reference lists. Methodological quality Two independent reviewers used the standard critical appraisal tool from JBI-MAStARI to assess the methodological qualities of the studies that matched with inclusion criteria. Data collectionA standard data form from JBI-MAStARI was used to extract the data across all included studies. Data synthesis Proportional Meta-analysis based on DerSimonian-Laird weights for the random effects model was used for statistical pooling through Stats Direct. Heterogeneity was assessed using Cochran Q. When statistical pooling is not possible, the findings are presented in narrative summary. Results A total of 753 patients were included in this review. All except one patient completed a total of 2298 cycles of rapid Rituximab infusions. Seventeen and one acute adverse reactions were reported among NHL and CLL patients respectively. There were five reactions which were not clearly stated if they were occurring in NHL or CLL patients. All were mild to moderate reactions except one patient developed severe reaction and withdrew from the study. Conclusions Rapid Rituximab infusion is safe for NHL patients especially in a 90-minute regimen. However, rapid rituximab infusion is not recommended for CLL patients due to lack of evidence. Implications for practice 90-minute rapid Rituximab infusion with or without steroid premedication is recommended for NHL patient at second and subsequently infusions. No recommendations can be made in relation to stage of disease or the presence of bulky disease or leucocytosis. It is not recommended, based on the current evidence, to use rapid Rituximab for CLL patients. Implications for research Further research is needed on the role of monoclonal antibodies development in rapid infusion, especially in the second and subsequent cycles. Currently, this review broadly establishes that rapid Rituximab infusion over 90 minutes is safe for NHL patients. However, more research and detailed analysis is needed to develop more specific guidelines." @default.
- W4247521257 created "2022-05-12" @default.
- W4247521257 creator A5007504229 @default.
- W4247521257 creator A5042599665 @default.
- W4247521257 date "2011-01-01" @default.
- W4247521257 modified "2023-10-17" @default.
- W4247521257 title "Acute adverse reactions of rapid Rituximab infusion among adult patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia" @default.
- W4247521257 cites W1592990112 @default.
- W4247521257 cites W1988217711 @default.
- W4247521257 cites W1998900344 @default.
- W4247521257 cites W2021755434 @default.
- W4247521257 cites W2052762949 @default.
- W4247521257 cites W2111968408 @default.
- W4247521257 cites W2111985824 @default.
- W4247521257 cites W2126497496 @default.
- W4247521257 cites W2133284467 @default.
- W4247521257 cites W2136935228 @default.
- W4247521257 cites W2246035211 @default.
- W4247521257 cites W2334647425 @default.
- W4247521257 doi "https://doi.org/10.11124/jbisrir-2011-69" @default.
- W4247521257 hasPublicationYear "2011" @default.
- W4247521257 type Work @default.
- W4247521257 citedByCount "2" @default.
- W4247521257 countsByYear W42475212572013 @default.
- W4247521257 countsByYear W42475212572022 @default.
- W4247521257 crossrefType "journal-article" @default.
- W4247521257 hasAuthorship W4247521257A5007504229 @default.
- W4247521257 hasAuthorship W4247521257A5042599665 @default.
- W4247521257 hasConcept C126322002 @default.
- W4247521257 hasConcept C143998085 @default.
- W4247521257 hasConcept C177713679 @default.
- W4247521257 hasConcept C197934379 @default.
- W4247521257 hasConcept C203014093 @default.
- W4247521257 hasConcept C2777938653 @default.
- W4247521257 hasConcept C2778461978 @default.
- W4247521257 hasConcept C2779338263 @default.
- W4247521257 hasConcept C2780653079 @default.
- W4247521257 hasConcept C2908647359 @default.
- W4247521257 hasConcept C71924100 @default.
- W4247521257 hasConcept C99454951 @default.
- W4247521257 hasConceptScore W4247521257C126322002 @default.
- W4247521257 hasConceptScore W4247521257C143998085 @default.
- W4247521257 hasConceptScore W4247521257C177713679 @default.
- W4247521257 hasConceptScore W4247521257C197934379 @default.
- W4247521257 hasConceptScore W4247521257C203014093 @default.
- W4247521257 hasConceptScore W4247521257C2777938653 @default.
- W4247521257 hasConceptScore W4247521257C2778461978 @default.
- W4247521257 hasConceptScore W4247521257C2779338263 @default.
- W4247521257 hasConceptScore W4247521257C2780653079 @default.
- W4247521257 hasConceptScore W4247521257C2908647359 @default.
- W4247521257 hasConceptScore W4247521257C71924100 @default.
- W4247521257 hasConceptScore W4247521257C99454951 @default.
- W4247521257 hasIssue "1" @default.
- W4247521257 hasLocation W42475212571 @default.
- W4247521257 hasOpenAccess W4247521257 @default.
- W4247521257 hasPrimaryLocation W42475212571 @default.
- W4247521257 hasRelatedWork W2019523579 @default.
- W4247521257 hasRelatedWork W2132818131 @default.
- W4247521257 hasRelatedWork W2154164804 @default.
- W4247521257 hasRelatedWork W2358268857 @default.
- W4247521257 hasRelatedWork W2414930736 @default.
- W4247521257 hasRelatedWork W2883201369 @default.
- W4247521257 hasRelatedWork W3215159064 @default.
- W4247521257 hasRelatedWork W4280583963 @default.
- W4247521257 hasRelatedWork W1829905293 @default.
- W4247521257 hasRelatedWork W2303208263 @default.
- W4247521257 hasVolume "9" @default.
- W4247521257 isParatext "false" @default.
- W4247521257 isRetracted "false" @default.
- W4247521257 workType "article" @default.